Literature DB >> 28011313

Prognostic Value of High-Sensitivity Cardiac Troponin T Compared with Risk Scores in Stable Cardiovascular Disease.

Moritz Biener1, Evangelos Giannitsis2, Manuel Kuhner1, Thomas Zelniker1, Matthias Mueller-Hennessen1, Mehrshad Vafaie1, Dietmar Trenk3, Franz-Josef Neumann3, Willibald Hochholzer3, Hugo A Katus1.   

Abstract

BACKGROUND: Risk stratification of patients with cardiovascular disease remains challenging despite consideration of risk scores.
METHODS: We aimed to evaluate the prognostic performance of high-sensitivity cardiac troponin T in a low-risk outpatient population presenting for nonsecondary and secondary prevention. All-cause mortality, a composite of all-cause mortality, acute myocardial infarction, and stroke (end point 2), and a composite of all-cause mortality, acute myocardial infarction, stroke and rehospitalization for acute coronary syndrome, and decompensated heart failure (end point 3) were defined. The prognostic performance of high-sensitivity cardiac troponin T on index visit was compared with the PROCAM score and 3 FRAMINGHAM subscores.
RESULTS: In 693 patients with a median follow-up of 796 days, we observed 16 deaths, 32 patients with end point 2, and 83 patients with end point 3. All risk scores performed better in the prediction of all-cause mortality in nonsecondary prevention (area under the curve [AUC]: PROCAM: 0.922 vs 0.523, P = .001, consistent for all other scores). In secondary prevention, high-sensitivity cardiac troponin T outperformed all risk scores in the prediction of all-cause mortality (ΔAUC: PROCAM: 0.319, P <.001, consistent for all other scores) and performed superiorly in the prediction of end point 2 compared with the PROCAM, FRAMINGHAM-Coronary Heart Disease, and FRAMINGHAM-Hard Coronary Heart Disease scores (ΔAUC: PROCAM: 0.176, P = .047, consistent for FRAMINGHAM-Coronary Heart Disease and FRAMINGHAM-Hard Coronary Heart Disease). In nonsecondary prevention, we observed a comparable prognostic performance of high-sensitivity cardiac troponin T and multivariable risk scores. Our findings on the prediction of all-cause mortality compared with the FRAMINGHAM-Hard Coronary Heart Disease score were confirmed in an independent validation cohort on 2046 patients.
CONCLUSIONS: High-sensitivity troponin T provides excellent risk stratification regarding all-cause mortality and all-cause mortality, acute myocardial infarction, and stroke in a secondary prevention cohort in whom risk scores perform poorly.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiovascular disease; Disease progression; High-sensitivity troponin T; Risk scores; Risk stratification

Mesh:

Substances:

Year:  2016        PMID: 28011313     DOI: 10.1016/j.amjmed.2016.11.028

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  4 in total

Review 1.  [A review on the clinical application of high-sensitivity cardiac troponin T in neonatal diseases].

Authors:  Tie-Geng Li
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2019-09

Review 2.  [Essential cardiac biomarkers in the differential diagnosis of acute chest pain : An update].

Authors:  M Vafaie; E Giannitsis; H A Katus
Journal:  Herz       Date:  2018-08       Impact factor: 1.443

3.  Risk prediction in stable cardiovascular disease using a high-sensitivity cardiac troponin T single biomarker strategy compared to the ESC-SCORE.

Authors:  Moritz Biener; Evangelos Giannitsis; Manuel Kuhner; Thomas Zelniker; Matthias Mueller-Hennessen; Mehrshad Vafaie; Kiril M Stoyanov; Franz-Josef Neumann; Hugo A Katus; Willibald Hochholzer; Christian Marc Valina
Journal:  Open Heart       Date:  2018-04-25

4.  Cardiac Biomarkers and Subsequent Risk of Hospitalization With Bleeding in the Community: Atherosclerosis Risk in Communities Study.

Authors:  Lena Mathews; Junichi Ishigami; Ning Ding; Ron C Hoogeveen; Anna Kucharska-Newton; Christie M Ballantyne; Rebecca Gottesman; Elizabeth Selvin; Kunihiro Matsushita
Journal:  J Am Heart Assoc       Date:  2020-03-02       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.